curasan AG

euro adhoc: curasan AG
Quarterly or Semiannual Financial Statements
curasan AG: preliminary results for the second quarter Revenue + 35%, substantial improvement in earnings

@@start.t1@@--------------------------------------------------------------------------------   Disclosure announcement transmitted by euro adhoc.   The issuer is responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@


Kleinostheim, July 21, 2005 - curasan AG (WKN 549 453) today announced its financial results for the second quarter ended June 30, 2005. In the second quarter, the company generated revenue of EUR 2.3 million (Q2 2004: EUR 1.7 million) and a loss before interest and taxes of EUR 519 thousand (Q2 2004: loss of EUR 848 thousand).The net loss for the period improved to EUR 311 thousand (Q2 2004: loss of EUR 657 thousand).

Revenue was 35% higher than in the same period a year ago. At 38%, year-on-year EBIT growth was even more pronounced.

The double-digit increase in revenue was attributable mainly to the positive development of the company’s international business - particularly with the new curasan-product curavisc® against joint arthrosis - as well as higher sales volumes within the area of bone regeneration and from the haemostatic product stypro®.

The company also continued to apply a stringent programme of cost management. As a result of savings within this area, earnings improved substantially in the second quarter.

In addition, the successful placement of 250,000 shares issued as part of a capital increase in the second quarter raised awareness among investors and allowed curasan AG to regain a more prominent position within the financial markets. The company’s management sees the first-half results as confirmation of curasan’s turnaround forecast for 2006.

The full quarterly report will be published on August 11 and can be accessed via the company’s website.

About curasan AG: curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a leading innovator within the growth market of bone and tissue regeneration. The company has developed a comprehensive product range centred around its synthetic bone regeneration material Cerasorb®, for use in soft and hard tissue. curasan AG's main goal is to occupy a leading position as a global specialist in Regenerative Medicine. For further information, please visit curasan’s corporate website at:

End of ad hoc release

@@start.t2@@end of announcement                                                 euro adhoc 21.07.2005 08:44:53

ots Originaltext: curasan AG
Im Internet recherchierbar:

Further inquiry note:
Dr. Erwin Amashaufer, curasan AG, Tel. +49 (6027) 46 86 465, eMail:

Branche: Biotechnology
ISIN:      DE0005494538
WKN:        549453
Börsen:    Frankfurter Wertpapierbörse
                Berliner Wertpapierbörse
                Hamburger Wertpapierbörse
                Baden-Württembergische Wertpapierbörse
                Börse Düsseldorf
                Niedersächsische Börse zu Hannover
                Bayerische Börse
                Bremer Wertpapierbörse (BWB)

Weitere Meldungen: curasan AG

Das könnte Sie auch interessieren: